Presentation is loading. Please wait.

Presentation is loading. Please wait.

Markov model scheme. Markov model scheme. Patients start (state 0) with uncomplicated PCI revascularisation; then cycle between health states until death.

Published byAlexandra Clarke Modified over 5 years ago

Similar presentations

Presentation on theme: "Markov model scheme. Markov model scheme. Patients start (state 0) with uncomplicated PCI revascularisation; then cycle between health states until death."— Presentation transcript:

1 Markov model scheme. Markov model scheme. Patients start (state 0) with uncomplicated PCI revascularisation; then cycle between health states until death occurs or the 5-year period ends. Dotted boxes are events that cause a change of state. Each cycle is 6 months. The health states are equivalent for BMS and DES; however, probabilities and initial costs vary with the strategy. BMS, bare-metal stents; DES, drug-eluting stents; MI, myocardial infarction; PCI, percutaneous coronary intervention. Louise Baschet et al. Open Heart 2016;3:e000445 ©2016 by British Cardiovascular Society

Download ppt "Markov model scheme. Markov model scheme. Patients start (state 0) with uncomplicated PCI revascularisation; then cycle between health states until death."

Similar presentations

Drug-Eluting Stent Mortality Meta-Analysis Presented at European Society of Cardiology Scientific Congress, September 2006 Presented by Dr. Alain J. Nordmann.

Drug-Eluting Stent Mortality Meta-Analysis Presented at European Society of Cardiology Scientific Congress, September 2006 Presented by Dr. Alain J. Nordmann.
Discontinuation of medication after nonfatal event: MI

Discontinuation of medication after nonfatal event: MI
Subgroup analyses for mortality after treatment with coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI). LAD, left anterior.

Subgroup analyses for mortality after treatment with coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI). LAD, left anterior.
The MASS-DAC Study.

The MASS-DAC Study.
Algorithm for preoperative management of patients taking antiplatelet therapy. ACS, acute coronary syndrome; BMS, bare metal stent; DES, drug-eluting stent;

Algorithm for preoperative management of patients taking antiplatelet therapy. ACS, acute coronary syndrome; BMS, bare metal stent; DES, drug-eluting stent;
Supplementary Table 1 Independent Predictors of 2-Year Mortality

Supplementary Table 1 Independent Predictors of 2-Year Mortality
NORSTENT Trial design: Patients with obstructive coronary artery disease were randomized to a drug-eluting stent (DES) (n = 4,504) versus a bare-metal.

NORSTENT Trial design: Patients with obstructive coronary artery disease were randomized to a drug-eluting stent (DES) (n = 4,504) versus a bare-metal.
Copyright © 2013 American Medical Association. All rights reserved.

Copyright © 2013 American Medical Association. All rights reserved.
Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have.

Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have.
Unadjusted 3-year cumulative incidence of adverse events after saphenous vein graft (SVG) percutaneous coronary intervention (PCI) with embolic protection.

Unadjusted 3-year cumulative incidence of adverse events after saphenous vein graft (SVG) percutaneous coronary intervention (PCI) with embolic protection.
Circ Cardiovasc Interv

Circ Cardiovasc Interv
Catheter-Based Treatment of Coronary Artery Disease

Catheter-Based Treatment of Coronary Artery Disease
Presented by Dr. Leif Thuesen

Presented by Dr. Leif Thuesen
Glenn N. Levine et al. JACC 2016;68:

Glenn N. Levine et al. JACC 2016;68:
Baseline characteristics of patients

Baseline characteristics of patients
Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
J. Trevor Posenau, MD, Daniel M. Wojdyla, MS, Linda K

J. Trevor Posenau, MD, Daniel M. Wojdyla, MS, Linda K
Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction  P.-G. Chassot, A. Delabays, D.R. Spahn 

Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction  P.-G. Chassot, A. Delabays, D.R. Spahn 

Similar presentations

Ads by Google